Protective efficacy of a single immunization with capripoxvirus-vectored recombinant peste des petits ruminants vaccines in presence of pre-existing immunity

Vaccine

Volumn 32, Issue 30, 2014, Pages 3772-3779

  Caufour, Philippe ^a   Rufael, Tesfaye ^b   Lamien, Charles Euloge ^c   Lancelot, Renaud ^a   Kidane, Menbere ^b   Awel, Dino ^b   Sertse, Tefera ^b   Kwiatek, Olivier ^a   Libeau, Geneviève ^a   Sahle, Mesfin ^b   Diallo, Adama ^c   Albina, Emmanuel ^a  

^a UMR ASTRE   (France)

^b National Animal health Diagnosis and Investigation Center (NAHDIC)   (Ethiopia)

^c INTERNATIONAL ATOMIC ENERGY AGENCY   (Austria)

Author keywords

Capripoxvirus; Peste des petits ruminants; Pre existing immunity; Recombinant viral vector; Vaccine efficacy

Indexed keywords

NEUTRALIZING ANTIBODY; PESTE DES PETITS RUMINANTS VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS FUSION PROTEIN; VIRUS HEMAGGLUTININ; VIRUS VACCINE; VIRUS VECTOR; RECOMBINANT VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CAPRIPOXVIRUS; DRUG EFFICACY; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW UP; HUMORAL IMMUNITY; IMMUNITY; MALE; MASS IMMUNIZATION; NONHUMAN; PESTE DES PETITS RUMINANTS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SHEEP; ANIMAL; BLOOD; GOAT; GOAT DISEASES; IMMUNOLOGY; PESTE-DES-PETITS-RUMINANTS; PESTE-DES-PETITS-RUMINANTS VIRUS; SERODIAGNOSIS;

ANIMALS; ANTIBODIES, VIRAL; CAPRIPOXVIRUS; GOAT DISEASES; GOATS; MALE; NEUTRALIZATION TESTS; PESTE-DES-PETITS-RUMINANTS; PESTE-DES-PETITS-RUMINANTS VIRUS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84922219532     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.05.025     Document Type: Article

References (55)

1. Gibbs E.P., Taylor W.P., Lawman M.J., Bryant J. Classification of peste des petits ruminants virus as the fourth member of the genus Morbillivirus. Intervirology 1979, 11:268-274.
2. Barrett T., Banyard A.C., Diallo A. Molecular biology of the morbilliviruses. Rinderpest and peste des petits ruminants 2006, 31-67. Academic Press, Oxford. T. Barrett, P.P. Pastoret, W.P. Taylor (Eds.).
3. Rowland A.C., Scott G.R., Hill D.H. The pathology of an erosive stomatitis and enteritis in West-African dwarf goats. J Pathol 1969, 98:83-87.
4. Roeder P.L., Taylor W.P. Rinderpest. The veterinary clinics of North America food animal practice 2002, vol. 18:515-547. ix.
5. Banyard A.C., Parida S., Batten C., Oura C., Kwiatek O., Libeau G. Global distribution of peste des petits ruminants virus and prospects for improved diagnosis and control. J Gen Virol 2010, 91:2885-2897.
6. Diallo A. Control of peste des petits ruminants: classical and new generation vaccines. Dev Biol 2003, 114:113-119.
7. Babiuk S., Bowden T.R., Boyle D.B., Wallace D.B., Kitching R.P. Capripoxviruses: an emerging worldwide threat to sheep, goats and cattle. Transbound Emerg Dis 2008, 55:263-272.
8. Kitching R.P. Vaccines for lumpy skin disease, sheep pox and goat pox. Dev Biol 2003, 114:161-167.
9. Kitching R.P., Hammond J.M., Taylor W.P. A single vaccine for the control of capripox infection in sheep and goats. Res Vet Sci 1987, 42:53-60.
10. Berhe G., Minet C., Le Goff C., Barrett T., Ngangnou A., Grillet C., et al. Development of a dual recombinant vaccine to protect small ruminants against peste-des-petits-ruminants virus and capripoxvirus infections. J Virol 2003, 77:1571-1577.
11. Diallo A., Minet C., Berhe G., Le Goff C., Black D.N., Fleming M., et al. Goat immune response to capripox vaccine expressing the hemagglutinin protein of peste des petits ruminants. Ann N Y Acad Sci 2002, 969:88-91.
12. Ngichabe C.K., Wamwayi H.M., Barrett T., Ndungu E.K., Black D.N., Bostock C.J. Trial of a capripoxvirus-rinderpest recombinant vaccine in African cattle. Epidemiol Infect 1997, 118:63-70.
13. Ngichabe C.K., Wamwayi H.M., Ndungu E.K., Mirangi P.K., Bostock C.J., Black D.N., et al. Long term immunity in African cattle vaccinated with a recombinant capripox-rinderpest virus vaccine. Epidemiol Infect 2002, 128:343-349.
14. Romero C.H., Barrett T., Chamberlain R.W., Kitching R.P., Fleming M., Black D.N. Recombinant capripoxvirus expressing the hemagglutinin protein gene of rinderpest virus: protection of cattle against rinderpest and lumpy skin disease viruses. Virology 1994, 204:425-429.
15. Romero C.H., Barrett T., Kitching R.P., Carn V.M., Black D.N. Protection of cattle against rinderpest and lumpy skin disease with a recombinant capripoxvirus expressing the fusion protein gene of rinderpest virus. Vet Rec 1994, 135:152-154.
16. Cottingham M.G., Carroll M.W. Recombinant MVA vaccines: dispelling the myths. Vaccine 2013, 31(39):4247-4251.
17. Rollier C.S., Reyes-Sandoval A., Cottingham M.G., Ewer K., Hill A.V. Viral vectors as vaccine platforms: deployment in sight. Curr Opin Immunol 2011, 23:377-382.
18. Saxena M., Van T.T., Baird F.J., Coloe P.J., Smooker P.M. Pre-existing immunity against vaccine vectors-friend or foe. Microbiology 2013, 159:1-11.
19. Chen W., Hu S., Qu L., Hu Q., Zhang Q., Zhi H., et al. A goat poxvirus-vectored peste-des-petits-ruminants vaccine induces long-lasting neutralization antibody to high levels in goats and sheep. Vaccine 2010, 28:4742-4750.
20. Gari G., Biteau-Coroller F., LeGoff C., Caufour P., Roger F. Evaluation of indirect fluorescent antibody test (IFAT) for the diagnosis and screening of lumpy skin disease using Bayesian method. Vet Microbiol 2008, 129:269-280.
21. Perrin A., Albina E., Breard E., Sailleau C., Prome S., Grillet C., et al. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine 2007, 25:6774-6783.
22. Manual of diagnostic tests & vaccines for terrestrial animals 2012, World organization for Animal Health, Paris. 7th ed.
23. Rossiter P.B., Jessett D.M., Taylor W.P. Microneutralisation systems for use with different strains of peste des petits ruminants virus and rinderpest virus. Trop Anim Health Prod 1985, 17:75-81.
24. Michaud V., Gil P., Kwiatek O., Prome S., Dixon L., Romero L., et al. Long-term storage at tropical temperature of dried-blood filter papers for detection and genotyping of RNA and DNA viruses by direct PCR. J Virol Methods 2007, 146:257-265.
25. Couacy-Hymann E., Roger F., Hurard C., Guillou J.P., Libeau G., Diallo A. Rapid and sensitive detection of peste des petits ruminants virus by a polymerase chain reaction assay. J Virol Methods 2002, 100:17-25.
26. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995, 57:289-300.
27. Lamien C.E., Lelenta M., Goger W., Silber R., Tuppurainen E., Matijevic M., et al. Real time PCR method for simultaneous detection, quantitation and differentiation of capripoxviruses. J Virol Methods 2011, 171:134-140.
28. Kwiatek O., Keita D., Gil P., Fernandez-Pinero J., Jimenez Clavero M.A., Albina E., et al. Quantitative one-step real-time RT-PCR for the fast detection of the four genotypes of PPRV. J Virol Methods 2010, 165:168-177.
29. Soi R.K., Rurangirwa F.R., McGuire T.C., Rwambo P.M., DeMartini J.C., Crawford T.B. Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine. Clin Vaccine Immunol 2010, 17:1842-1849.
30. Wallace D.B., Ellis C.E., Espach A., Smith S.J., Greyling R.R., Viljoen G.J. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 2006, 24:7181-7189.
31. Flexner C., Murphy B.R., Rooney J.F., Wohlenberg C., Yuferov V., Notkins A.L., et al. Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen. Nature 1988, 335:259-262.
32. Murphy B.R., Olmsted R.A., Collins P.L., Chanock R.M., Prince G.A. Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses. J Virol 1988, 62:3907-3910.
33. Yilma T., Hsu D., Jones L., Owens S., Grubman M., Mebus C., et al. Protection of cattle against rinderpest with vaccinia virus recombinants expressing the HA or F gene. Science 1988, 242:1058-1061.
34. Belsham G.J., Anderson E.C., Murray P.K., Anderson J., Barrett T. Immune response and protection of cattle and pigs generated by a vaccinia virus recombinant expressing the F protein of rinderpest virus. Vet Rec 1989, 124:655-658.
35. Giavedoni L., Jones L., Mebus C., Yilma T. A vaccinia virus double recombinant expressing the F and H genes of rinderpest virus protects cattle against rinderpest and causes no pock lesions. Proc Natl Acad Sci USA 1991, 88:8011-8015.
36. Yamanouchi K., Inui K., Sugimoto M., Asano K., Nishimaki F., Kitching R.P., et al. Immunisation of cattle with a recombinant vaccinia vector expressing the haemagglutinin gene of rinderpest virus. Vet Rec 1993, 132:152-156.
37. Yamanouchi K., Barrett T. Progress in the development of a heat-stable recombinant rinderpest vaccine using an attenuated vaccinia virus vector. Rev Sci Tech 1994, 13:721-735.
38. Inui K., Barrett T., Kitching R.P., Yamanouchi K. Long-term immunity in cattle vaccinated with a recombinant rinderpest vaccine. Vet Rec 1995, 137:669-670.
39. Ohishi K., Kamata H., Ohkubo S., Yamanouchi K., Kai C. Construction of recombinant vaccinia virus expressing Rinderpest Virus nucleocapsid protein and its immunogenicity in mice. J Vet Med Sci 1998, 60:655-656.
40. Verardi P.H., Aziz F.H., Ahmad S., Jones L.A., Beyene B., Ngotho R.N., et al. Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteins. J Virol 2002, 76:484-491.
41. Chandran D., Reddy K.B., Vijayan S.P., Sugumar P., Rani G.S., Kumar P.S., et al. MVA recombinants expressing the fusion and hemagglutinin genes of PPRV protects goats against virulent challenge. Indian J Microbiol 2010, 50:266-274.
42. Sato H., Yoneda M., Honda T., Kai C. Recombinant vaccines against the mononegaviruses-what we have learned from animal disease controls. Virus Res 2011, 162:63-71.
43. Belyakov I.M., Moss B., Strober W., Berzofsky J.A. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc Natl Acad Sci USA 1999, 96:4512-4517.
44. Cooney E.L., Collier A.C., Greenberg P.D., Coombs R.W., Zarling J., Arditti D.E., et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 1991, 337:567-572.
45. Etlinger H.M., Altenburger W. Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus. Vaccine 1991, 9:470-472.
46. Gudmundsdotter L., Nilsson C., Brave A., Hejdeman B., Earl P., Moss B., et al. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009, 27:4468-4474.
47. Kanesa-thasan N., Sun W., Kim-Ahn G., Van Albert S., Putnak J.R., King A., et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 2001, 19:3179-3188.
48. Kannanganat S., Nigam P., Velu V., Earl P.L., Lai L., Chennareddi L., et al. Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine. J Immunol 2010, 185:7262-7273.
49. Kitabatake M., Inoue S., Yasui F., Yokochi S., Arai M., Morita K., et al. SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus. Vaccine 2007, 25:630-637.
50. Kundig T.M., Kalberer C.P., Hengartner H., Zinkernagel R.M. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 1993, 11:1154-1158.
51. Ramirez J.C., Gherardi M.M., Rodriguez D., Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 2000, 74:7651-7655.
52. Reyes-Sandoval A., Rollier C.S., Milicic A., Bauza K., Cottingham M.G., Tang C.K., et al. Mixed vector immunization with recombinant adenovirus and MVA can improve vaccine efficacy while decreasing antivector immunity. Mol Ther 2012, 20:1633-1647.
53. Rooney J.F., Wohlenberg C., Cremer K.J., Moss B., Notkins A.L. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J Virol 1988, 62:1530-1534.
54. Sharpe S., Polyanskaya N., Dennis M., Sutter G., Hanke T., Erfle V., et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity. J Gen Virol 2001, 82:2215-2223.
55. Yang Z.Y., Wyatt L.S., Kong W.P., Moodie Z., Moss B., Nabel G.J. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 2003, 77:799-803.